SLSBio(Specialty Lab Solution Bio) KRX:246250KOSDAQ
에스엘에스바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, SLSBio(Specialty Lab Solution Bio) reported revenue of ₩1.3bn, down 18.7% year on year, and an operating loss of ₩898m. SLSBio(Specialty Lab Solution Bio) (에스엘에스바이오) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals 4 quarters of losses Screener
SLSBio(Specialty Lab Solution Bio) quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩1.3bn | -18.7% | −₩898m margin −69.4% | −₩973m |
| Q1 2026 | ₩958m | -45.4% | −₩950m margin −99.2% | −₩939m |
| Q4 2025 derived | ₩341m | -81.3% | −₩1.4bn | −₩1.6bn |
| Q3 2025 | ₩296m | -86.0% | −₩1.8bn | −₩1.9bn |
| Q2 2025 | ₩1.6bn | -33.0% | −₩674m margin −42.4% | −₩1.2bn |
| Q1 2025 | ₩1.8bn | -14.3% | −₩220m margin −12.5% | −₩199m |
| Q4 2024 derived | ₩1.8bn | -26.2% | −₩196m margin −10.7% | −₩310m |
| Q3 2024 | ₩2.1bn | -0.5% | ₩108m margin 5.1% | ₩161m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
SLSBio(Specialty Lab Solution Bio) top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.